Bill Description: House Bill 530 would impose new regulations on health carriers and cap the deductibles they can charge for certain classes of medications.
Rating: -1
NOTE: House Bill 530 is related to Senate Bill 1034 (2019).
Does it give government any new, additional, or expanded power to prohibit, restrict, or regulate activities in the free market? Conversely, does it eliminate or reduce government intervention in the market?
House Bill 530 would create Section 41-1854, Idaho Code, to require that health benefit plans either charge the same or lower copayment, deductible, or coinsurance amount for “orally administered anticancer medication” as they do for “injected or intravenously administered anticancer medication” or charge no more than $250 for a 30-day supply of orally administered anticancer medication.
The bill would further prohibit an insurance provider from “increasing the copayment, deductible, or coinsurance amount required for an anticancer medication covered under the health benefit plan; or reclassifying benefits with respect to anticancer medications.”
These regulations undermine the free market and violate freedom of contract by overriding and prohibiting certain policy agreements between providers of health benefit plans and their policyholders.
(-1)
